Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 421

1.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.

Cancer Res. 2009 Mar 1;69(5):1851-7. doi: 10.1158/0008-5472.CAN-08-2466. Epub 2009 Feb 17.

2.

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.

PMID:
23429431
3.

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.

Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25. Review.

PMID:
24666267
4.

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.

Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, Lamba S, Veronese S, Frattini M, Bardelli A, Siena S.

PLoS One. 2009 Oct 2;4(10):e7287. doi: 10.1371/journal.pone.0007287.

5.

PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A, Rajdev L, Mariadason JM, Tanaka K, Goel S.

Clin Colorectal Cancer. 2012 Jun;11(2):143-50. doi: 10.1016/j.clcc.2011.12.001. Epub 2012 Jan 28.

6.

Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.

Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, Ding H, Mao C, Tang JL.

Int J Cancer. 2013 Oct 15;133(8):1914-25. doi: 10.1002/ijc.28153. Epub 2013 Jul 13. Review. Erratum in: Int J Cancer. 2014 Jul 15;135(2):E2.

7.

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.

Mao C, Yang ZY, Hu XF, Chen Q, Tang JL.

Ann Oncol. 2012 Jun;23(6):1518-25. doi: 10.1093/annonc/mdr464. Epub 2011 Oct 29. Review.

PMID:
22039088
8.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S.

Lancet Oncol. 2010 Aug;11(8):753-62. doi: 10.1016/S1470-2045(10)70130-3. Epub 2010 Jul 8.

PMID:
20619739
9.

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.

Soeda H, Shimodaira H, Watanabe M, Suzuki T, Gamoh M, Mori T, Komine K, Iwama N, Kato S, Ishioka C.

Int J Clin Oncol. 2013 Aug;18(4):670-7. doi: 10.1007/s10147-012-0422-8. Epub 2012 May 26.

PMID:
22638623
10.

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID.

Eur J Cancer. 2010 Jul;46(11):1997-2009. doi: 10.1016/j.ejca.2010.03.036. Epub 2010 Apr 21.

PMID:
20413299
11.

The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.

Lin JK, Lin AJ, Lin CC, Lan YT, Yang SH, Li AF, Chang SC.

J Surg Oncol. 2011 Nov 1;104(6):661-6. doi: 10.1002/jso.21993. Epub 2011 Jun 13.

PMID:
21671463
12.

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A.

J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24. doi: 10.1093/jnci/djp280. Epub 2009 Sep 8. Review.

13.

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabiso O, Girlando S, Soini B, Spitale A, Di Nicolantonio F, Saletti P, Crippa S, Mazzucchelli L, Marchetti A, Bardelli A, Frattini M.

Clin Cancer Res. 2011 Jul 15;17(14):4901-14. doi: 10.1158/1078-0432.CCR-10-3137. Epub 2011 Jun 1.

14.

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.

László L.

Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.

15.

Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.

Kishiki T, Ohnishi H, Masaki T, Ohtsuka K, Ohkura Y, Furuse J, Sugiyama M, Watanabe T.

Oncol Rep. 2014 Jul;32(1):57-64. doi: 10.3892/or.2014.3179. Epub 2014 May 15.

PMID:
24839940
16.

Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.

Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.

Ann Surg. 2010 Feb;251(2):254-60. doi: 10.1097/SLA.0b013e3181bc9d96.

PMID:
20010090
17.

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.

Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, Lambrechts D, Van Cutsem E, Tejpar S.

Clin Cancer Res. 2009 May 1;15(9):3184-8. doi: 10.1158/1078-0432.CCR-08-2961. Epub 2009 Apr 14.

18.

[Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].

Fabian P, Berkovcová J.

Cesk Patol. 2011 Oct;47(4):154-8. Review. Czech.

PMID:
22145213
19.

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.

Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G.

BMC Cancer. 2013 Feb 2;13:49. doi: 10.1186/1471-2407-13-49.

20.

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.

Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, Pilotti S.

Ann Oncol. 2009 Jan;20(1):84-90. doi: 10.1093/annonc/mdn541. Epub 2008 Jul 31.

PMID:
18669866

Supplemental Content

Support Center